secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ernexa Therapeutics Inc. (ERNA)
CIK:        0000748592
Form:       8-K
Filed at:   2026-07-02T20:30:32+00:00
Accession:  0001493152-26-031920
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ernexa Therapeutics shareholders elect directors, ratify auditor, approve 2026 equity plan
--------------------------------------------------------------------------------

- All five director nominees elected: Bristol, Cicala, Luther, Ratner, Wexler; broker non-votes 161,165.
- Ratification of Haskell & White LLP as auditor for FY 2026: 590,236 for, 29,010 against, 495 abstentions.
- Approval of 2026 Omnibus Equity Incentive Plan: 363,640 for, 94,840 against, 96 abstentions, 161,165 broker non-votes.
- Quorum of 53.13% (619,741 of 1,166,333 shares) represented at the July 1, 2026 annual meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/748592/000149315226031920/0001493152-26-031920-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/748592/000149315226031920/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-031920

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer